For instance, the promising results from clinical trials involving triple combination therapy with BRAF-MEK inhibitors and anti-PD-L1 antibodies in BRAF-mutated metastatic melanoma [12] may take advantage of this pro-inflammatory component. The gene discussed is MAP2K7; the disease is metastatic melanoma.